Anna Roszmann
Gdansk, PM, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Loss of therapeutic efficacy following the switch from levodopa/carbidopa intestinal gel therapy to subcutaneous foslevodopa/foscarbidopa infusion in a patient with advanced Parkinson's disease.
Journal: Neurologia i neurochirurgia polska
Published: September 20, 2025
Levodopa and dopamine agonist phobia in Parkinson's Disease - does it really matter? A survey on treatment patterns in Polish tertiary centres.
Journal: Neurologia i neurochirurgia polska
Published: October 22, 2024
Response to 'Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out'.
Journal: Neurologia i neurochirurgia polska
Published: July 19, 2023
2-Methoxyestradiol and Hydrogen Peroxide as Promising Biomarkers in Parkinson's Disease.
Journal: Molecular neurobiology
Published: May 04, 2023
Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies.
Journal: International review of neurobiology
Published: October 08, 2022
The Effect of Frailty Syndrome on the Quality of Life of Individuals with Parkinson's Disease: A Pilot Observational and Multicenter Study on the Polish Population.
Journal: International journal of environmental research and public health
Published: October 01, 2022
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study.
Journal: Parkinsonism & related disorders
Published: August 22, 2022
Acute/subacutae demyelinating polyneuropathy in Parkinson's Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report.
Journal: Neurologia i neurochirurgia polska
Published: July 20, 2022
Regulation of Mitochondrial Dynamics in Parkinson's Disease-Is 2-Methoxyestradiol a Missing Piece?
Journal: Antioxidants (Basel, Switzerland)
Published: December 14, 2020
BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease.
Journal: Neuroscience letters
Published: August 13, 2013
Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Journal: Pharmacogenetics and genomics
Published: August 15, 2012
Last Updated: 09/26/2026